Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 8/20 | 0.34 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.33 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.33 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21312600 | 0.83 | PPARG (0.43) | HAO1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL25464506 | 0.82 | PRKAG1 (0.38) | HAO1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL25463985 | 0.81 | MKNK1 (0.46) | HAO1 | |
| SCHEMBL25464287 | 0.81 | HAO1 (0.38) | HAO1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL25463615 | 0.81 | HAO1 (0.38) | HAO1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23319997 | 0.80 | DHODH (0.40) | HAO1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23320028 | 0.79 | PPARG (0.48) | — | |
| SCHEMBL29968357 | 0.79 | PPARG (0.48) | — | |
| SCHEMBL21296970 | 0.79 | ALPL (0.42) | HAO1PRKAG1PRKAA1PRKAB1MGLL | |
| SCHEMBL21296854 | 0.79 | HAO1 (0.44) | HAO1PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | XDH, DUOX1, PNPO | HAO1 6/4885PRKAB2 3843/4885PRKAG1 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.